

CONCERNING: Legislation to establish a regulatory pathway for biosimilars with 12 years of data exclusivity, in order to ensure affordable access to new treatments while encouraging labor job creation for the future

WHEREAS, the unions and companies of the Pharmaceutical Industry Labor-Management Association recognize that a strong domestic pharmaceutical industry providing innovative, affordable medicines is vital to the American people and the nation; and

WHEREAS, the U.S. biopharmaceutical industry provides hundreds of thousands of high-paying jobs and contributes over \$200 billion to the gross domestic product; and

WHEREAS, the Association recognizes the need to address issues of mutual interest and concern to the industry, its workers and all Americans, including: access to medicines and affordability of medicines; funding of innovative research and future cures; and maintaining a strong U.S. industry. In particular, our members work in building biopharmaceutical research and manufacturing facilities across the country, and also benefit from access to biologics and their potential follow-on versions; and

WHEREAS, our members have become aware and supportive of legislation that creates an approval pathway for follow-on biologic products, and the Association believes it is important for Congress to understand the impact this legislation could have on our membership, both positively and negatively; and

WHEREAS, the biotech revolution of the last twenty-five years has led to enormous job growth in the United States, with the U.S. biopharmaceutical sector employing more than 686,000 people and supporting another 2.5 million more jobs in other industries; and

WHEREAS, when facilities are built and maintained, companies rely on the highly-skilled labor our members provide. Thus, the industry needs to continue to grow here in the U.S. and policymakers should understand the relationship between its success and ours; therefore

BE IT RESOLVED, the Association believes it is essential to pass legislation this year allowing for a substantive data exclusivity pathway for biosimilars; and

BE IT FURTHER RESOLVED, any bill that gives the FDA the authority to approve follow-on biologics should preserve and grow U.S. jobs; and

BE IT FURTHER RESOLVED, the Association believes it is essential to craft the right balance between lowering the price for biologic products in the near—term and protecting the investment that leads to job growth in the future. We therefore believe 12 years of data exclusivity for biologics meets this threshold and ask Member of Congress and the President to give domestic jobs and innovation full consideration when finalizing legislation on this important matter; and

BE IT FURTHER RESOLVED, that copies of this resolution be forwarded to all Members of the United States Congress, as well as to the President of the United States.